Despite the widely known benefits of exercise and physical activity, adherence rates to these activities are poor. Understanding exercise facilitators, barriers, and preferences may provide an opportunity to personalize exercise prescription and improve adherence. The purpose of this study was to develop the Personalized Exercise Questionnaire (PEQ) to identify these facilitators, barriers, and preferences to exercise in people with osteoporosis. This study comprises two phases, instrument design and judgmental evidence. A panel of 42 experts was used to validate the instrument through quantitative (content validity) and qualitative (cognitive interviewing) methods. Content Validity Index (CVI) is the most commonly used method to calculate content validity quantitatively. There are two kinds of CVI: Item-CVI (I-CVI) and Scale-level CVI (S-CVI). Preliminary versions of this tool showed high content validity of individual items (I-CVI range: 0.50 to 1.00) and moderate to high overall content validity of the PEQ (S-CVI/UA = 0.63; S-CVI/Ave = 0.91). Through qualitative methods, items were improved until saturation was achieved. The tool consists of 6 domains and 38 questions. The 6 domains are: 1) support network; 2) access; 3) goals; 4) preferences; 5) feedback and tracking; and 6) barriers. There are 35 categorical questions and 3 open-ended items. Using an iterative approach, the development and evaluation of the PEQ demonstrated high item-content validity for assessing the facilitators, barriers, and preferences to exercise in people with osteoporosis. Upon further validation it is expected that this measure might be used to develop more client-centered exercise programs, and potentially improve adherence.

Objective: To determine the extent to which thigh intermuscular fat (IMF) and quadriceps muscle (QM) volumes explained variance in knee extensor strength and physical performance in women with radiographic knee osteoarthritis (ROA) and without.Methods: Baseline data from 125 women (age ≥50 years) in the Osteoarthritis Initiative study, with or at risk of knee ROA were included. Knee extensor strength was measured using a fixed force transducer, normalized to body mass (N/kg). Physical performance was the time required for 5 repeated chair stands (seconds). The IMF and QM volumes, normalized to height (cm³/meter), were yielded from analyses of T1‐weighted axial magnetic resonance images of the midthigh. Mean IMF and QM volumes, extensor strength, and physical performance were compared between women with and without ROA, controlling for age. Hierarchical multiple regressions determined whether IMF and QM volumes were related to strength and performance after controlling for age, ROA status (yes/no), alignment, and pain.Results: Compared to subjects with ROA, the subjects without ROA were stronger and performed chair stands faster (P < 0.05). After adjusting for age, those subjects without ROA had less mean ± SD IMF (61.1 ± 20.3 cm³/meter) compared to mean ± SD ROA (72.0 ± 25.0 cm³/meter; P < 0.05). In the entire sample, 21.1% of variance in knee extensor strength was explained by alignment, pain, and IMF. A model explaining 13.4% of variance in physical performance included OA status and IMF. QM volume was unrelated to strength and physical performance.Conclusion: IMF volume explained a small amount of variance in knee extensor strength and physical performance among women with or at risk of knee ROA.

To determine the known-group validity, a type of construct validity, and the test-retest reliability of a newly developed tool, the Personalized Exercise Questionnaire (PEQ), that assesses the barriers, facilitators, and preferences to exercise in individuals with low bone mass and osteoporosis. A comparative design was used to assess known-group validity and a test-retest design to examine the reproducibility. Ninety-five participants with low bone mass and osteoporosis were recruited from an outpatient clinic in Hamilton, Ontario. The questionnaire was administered to 95 participants at baseline and a subset of 42 participants completed the survey again one week later. The known-group validity of the PEQ was determined using four hypotheses that compared two known groups based on employment level, age, socioeconomic status, and physical activity level. The reproducibility of individual responses was analyzed using the Kappa Coefficient (κ). There was known-group validity for three of the four hypotheses. Test-retest reliability scores ranged from no agreement to almost perfect agreement; seven items had almost perfect agreement (κ: 0.81–1.00), 12 substantial agreement (κ: 0.68–0.74), six moderate agreement (κ: 0.56–0.60), two fair agreement (κ: 0.36–0.40), one slight agreement (κ = 0.23) and one no agreement (κ = − 0.03). Preliminary support for the usefulness of the PEQ is indicated since the majority of the items had at least substantial agreement and known-group validity was moderately supported for some items. This study was retrospectively registered with ClinicalTrials.gov , NCT03125590, on April 24, 2017.

Objective: To quantify rates of change in quadriceps muscle (QM) and intermuscular fat (IMF) volumes over 2 years in women in the Osteoarthritis Initiative (OAI) study and examine group differences between those with radiographic osteoarthritis (ROA) and those without ROA.Methods: The OAI database was queried for women ≥50 years of age in the incident and progression cohorts with and without ROA at baseline. Midthigh magnetic resonance imaging scans (15 contiguous slices, 5 mm slice thickness) of eligible women were randomly selected and anonymized. Image pairs were registered. QM and IMF were segmented in the 12 most proximal matching slices with the segmenter blinded to image time point. Age‐adjusted differences in QM and IMF volume changes between groups were tested using analysis of covariance.Results: Forty‐one women without ROA (mean ± SD age 60.7 ± 7.6 years) and 45 women with ROA (mean ± SD age 64.5 ± 6.7 years) were included. Mean ± SD QM and IMF volume changes in the non‐ROA group were −4.1 ± 11.1 cm³ and 3.4 ± 7.1 cm³, respectively, and −5.4 ± 13.5 cm³ and 3.1 ± 7.4 cm³ in the ROA group, respectively. Age‐adjusted between‐group differences in QM and IMF changes were not significant (P > 0.05).Conclusion: Two‐year changes in QM and IMF volumes appear consistent with aging and do not seem to be related to OA status. Direct comparison with a control cohort without OA risk factors could confirm this. Since group assignment was based on baseline data, there may have been women in the non‐ROA group who developed ROA over followup, resulting in some overlap between groups.

Almost all patients with SSc have gastrointestinal manifestations. Small intestinal bacterial overgrowth (SIBO) occurs in 30–60% of patients and leads to malnutrition and impaired quality of life. Recent systematic reviews have reported efficacy of treatments for SIBO, but these are not specific to patients with SSc. We conducted a systematic review of the evidence for all possible SIBO treatments in the SSc population. The following databases were searched: MEDLINE, EMBASE and the Cochrane Library, from database inception to 1 January 2017. All evidence for all possible SIBO treatments including antibiotics, prokinetics, probiotics and alternative treatments was included. Treatment outcomes included symptomatic relief or demonstrated SIBO eradication. Of 5295 articles, five non-randomized studies were reviewed with a total of 78 SSc patients with SIBO. One trial assessed octreotide while the remaining four trials investigated the effectiveness of ciprofloxacin, rifaximin, norfloxacin and metronidazole, and the combination of amoxicillin, ciprofloxacin and metronidazole. Studies were generally of low quality and most were un-controlled. Data indicate that, for some SSc patients, antibiotics can eradicate SIBO. There is a paucity of data reporting the effectiveness of either prokinetics or probiotics in SSc.